Teradyne DROPS 16% in Recent Weeks and 4 Fresh Analyst Insights

ArQule Inc. (NASDAQ:ARQL): According to Stifel Nicolaus, the data which is scheduled to be released in Q4 or 2013 could indicate that ArQule’s Tivantinib is able to treat colorectal cancer. Because the firm believes that there are a number of other positive catalysts, it keeps a Buy rating on the stock.

Don’t Miss: Is Amazon Ready to CHALLENGE the Apple iPhone?

LSI Corporation (NYSE:LSI): Maxim states that Seagate (NASDAQ:STX), who preannounced negative Q4 results last night, is the most largest LSI Corp. (NYSE:LSI) customer. According the the firm, LSI Corp.’s fundamental recovery will take some time, but it maintains a Buy rating and $8 price target on the stock.

Costco Wholesale Corporation (NASDAQ:COST): Bernstein claims that low comp growth, foreign exchange headwinds, gasoline prices, and merchandise margin reinvestment could cause Costco’s earnings results to be lower than consensus but valuation limits downside. The firm keeps an Outperform rating but raises price target from $80 to $88 on the stock.

Las Vegas Sands Corp. (NYSE:LVS): According to Macquarie and Macau, gaming data keep suggesting that the current slowdown is more pronounced. This comes as capacity increases, and will most likely impact operating leverage negatively, similar to 2008/2009.

Teradyne Inc. (NYSE:TER) stocks fell nearly 16% recently, but DA Davidson things the company has several growth drivers as the Buy rating on shares is reiterated.

Don’t Miss: Microsoft Stock: BUY or SELL?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.